Sexually Transmitted Diseases (STD) Testing Market Report 2026

The sexually transmitted diseases (std) testing market size has grown strongly in recent years. It will grow from $8.78 billion in 2025 to $9.52 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing awareness of sexual health, expansion of public health screening programs, improved laboratory diagnostic capabilities, rising prevalence of sexually transmitted infections, wider availability of testing services.

The sexually transmitted diseases (std) testing market size is expected to see strong growth in the next few years. It will grow to $13.05 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing demand for confidential testing solutions, rising investments in molecular diagnostics, expansion of telehealth-enabled testing, growing focus on preventive healthcare, increasing government initiatives for disease control. Major trends in the forecast period include increasing adoption of at-home std testing kits, rising use of molecular diagnostic technologies, growing integration of digital health platforms, expansion of rapid point-of-care testing, enhanced focus on early disease detection.

The rising prevalence of HIV is expected to drive the growth of the sexually transmitted diseases (STD) testing market in the coming years. HIV is a virus that attacks and destroys critical white blood cells, weakening the immune system and making the body more susceptible to infections and illnesses. The increase in HIV cases is largely due to declining awareness and prevention efforts, leading to higher engagement in risky behaviors, such as unprotected sex, and lower testing rates, particularly among young people. The growing incidence of HIV fuels demand for sexually transmitted disease (STD) testing by raising public and healthcare awareness, encouraging more individuals to undergo comprehensive testing for early detection and to prevent further transmission. For instance, in July 2024, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based intergovernmental organization, approximately 1.3 million people were newly infected with HIV in 2023, nearly three times higher than the 2025 target of fewer than 370,000 cases. Therefore, the rising prevalence of HIV is driving the growth of the sexually transmitted diseases (STD) testing market.

Major companies operating in the sexually transmitted diseases (STD) testing market are focusing on the development of advanced solutions, such as syphilis testing kits, to make testing more widely accessible. Syphilis testing kits are diagnostic tools that detect the presence of the Treponema pallidum bacteria, the causative agent of syphilis, using blood samples or other bodily fluids to enable timely diagnosis and treatment. For instance, in August 2023, iHealth Labs Inc., a US-based medical device company, launched the CheckMeSafe home collection kit for HIV and syphilis testing. The FDA-approved iHealth CheckMeSafe Home Collection kit allows individuals aged 18 and older to collect blood samples for HIV (I, II, P24 antigen) and syphilis testing at home. Samples can be mailed to the laboratory using a prepaid overnight label, with confidential results provided in as little as two days. The kit offers high accuracy, with sensitivity rates of up to 99.9% for HIV and 99.5% for syphilis. All analyses are conducted in a CLIA-certified and CAP-accredited laboratory, ensuring compliance with federal and state quality standards through regular inspections.

In December 2023, imaware, a US-based company specializing in at-home health testing kits, acquired the at-home consumer testing business of binx health. This acquisition strengthens imaware’s presence in the growing home-health testing market and expands its enterprise client base. Meanwhile, binx health continues to operate and expand its point-of-care molecular diagnostics division, which was not included in the deal. Binx health is a US-based provider of sexually transmitted disease (STD) testing solutions.

Major companies operating in the sexually transmitted diseases (std) testing market are F Hoffmann La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Becton Dickinson And Co., Hologic Inc., QuidelOrtho Corp., Bio-Rad Laboratories Inc., Cepheid, OraSure Technologies Inc., Meridian Bioscience Inc., Sekisui Diagnostics Ltd., Trinity Biotech Plc, Chembio Diagnostics Inc., Operon SA, Jal Medical Pte. Ltd., Anatolia Geneworks, CLIAwaived Inc., Avecon Healthcare Pvt. Ltd., AEHEALTH LIMITED.

North America was the largest region in the sexually transmitted diseases (STD) testing market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the sexually transmitted diseases (std) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sexually transmitted diseases (std) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the std testing market by increasing costs of imported diagnostic instruments, reagents, testing kits, and laboratory automation systems. Diagnostic laboratories and healthcare providers in North America and Europe are most affected due to reliance on imported molecular testing components, while Asia-Pacific faces cost pressure on manufacturing and export of consumables. These tariffs are raising testing costs and impacting screening program budgets. However, they are also encouraging local production of diagnostic kits, regional reagent manufacturing, and innovation in cost-efficient testing technologies.

The sexually transmitted diseases (std) testing market research report is one of a series of new reports that provides sexually transmitted diseases (std) testing market statistics, including sexually transmitted diseases (std) testing industry global market size, regional shares, competitors with a sexually transmitted diseases (std) testing market share, detailed sexually transmitted diseases (std) testing market segments, market trends and opportunities, and any further data you may need to thrive in the sexually transmitted diseases (std) testing industry. This sexually transmitted diseases (std) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sexually transmitted disease (STD) testing refers to the medical process of identifying infections that are primarily spread through sexual contact. It is essential for early diagnosis, helping to prevent complications and limit the spread of infections through timely treatment and counseling. Regular screening is often recommended for sexually active individuals, as many infections may be asymptomatic but still transmissible.

The primary products of sexually transmitted disease (STD) testing include instruments and services, consumables, and software. Instruments and services encompass the diagnostic equipment and support activities used in clinical settings to perform medical testing. These utilize both immunoassay and molecular diagnostic technologies and can be performed using blood, urine, swab, semen, and other sample types. STD testing applies to diseases such as chlamydia, gonorrhea, syphilis, HIV/AIDS, and herpes simplex virus (HSV), and serves end users including individuals, healthcare providers, health insurance companies, government health agencies, NGOs, and community health organizations.

The sexually transmitted diseases (STD) testing market consists of revenues earned by entities by providing services such as confidential testing, walk-in clinic testing, online test ordering, telehealth consultations, and partner notification services. The market value includes the value of related goods sold by the service provider or included within the service offering. The sexually transmitted diseases (STD) testing market also includes sales of at-home test kits, multi-infection panel kits, blood collection devices, biohazard specimen bags, and portable sample storage containers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.